Clinical Trial Update: A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of pridopidine (ACR16) for Huntington's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Pridopidine (pridopidine)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-08-31